Table 1.

Results of cost utility analyses under scenario A

	New Drug	Standard of Care	Increment
a. Treatment of a Patient’s Rare Disease
QALYs	4.45	4.2	0.25
Weighted QALYs	8.9	8.4	0.5
Costs	$42,000	$19,000	$23,000
Incremental cost per QALY gained			$92,000
Incremental cost per weighted QALY gained			$46,000
b. Treatment of a Patient’s Co-morbidity
QALYs	4.5	4.2	0.3
Weighted QALYs	4.5	4.2	0.3
Costs	$33.550	$19,000	$14,550
Incremental cost per QALY gained			$48,500
Incremental cost per weighted QALY gained			$48,500